GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Daiichi Sankyo Co Ltd (OTCPK:DSNKY) » Definitions » Price-to-Owner-Earnings

Daiichinkyo Co (Daiichinkyo Co) Price-to-Owner-Earnings : 20.57 (As of Apr. 26, 2024)


View and export this data going back to 2008. Start your Free Trial

What is Daiichinkyo Co Price-to-Owner-Earnings?

As of today (2024-04-26), Daiichinkyo Co's share price is $30.86. Daiichinkyo Co's Owner Earnings per Share (TTM) ended in Mar. 2024 was $1.50. It's Price-to-Owner-Earnings for today is 20.57.


The historical rank and industry rank for Daiichinkyo Co's Price-to-Owner-Earnings or its related term are showing as below:

DSNKY' s Price-to-Owner-Earnings Range Over the Past 10 Years
Min: 4.2   Med: 36.98   Max: 276.95
Current: 20.53

During the past 13 years, the highest Price-to-Owner-Earnings of Daiichinkyo Co was 276.95. The lowest was 4.20. And the median was 36.98.


DSNKY's Price-to-Owner-Earnings is ranked better than
62.95% of 421 companies
in the Drug Manufacturers industry
Industry Median: 27.64 vs DSNKY: 20.53

As of today (2024-04-26), Daiichinkyo Co's share price is $30.86. Daiichinkyo Co's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2024 was $0.72. Therefore, Daiichinkyo Co's PE Ratio for today is 42.80.

As of today (2024-04-26), Daiichinkyo Co's share price is $30.86. Daiichinkyo Co's EPS without NRI for the trailing twelve months (TTM) ended in was $0.72. Therefore, Daiichinkyo Co's PE Ratio without NRI for today is 42.80.

During the past 13 years, Daiichinkyo Co's highest PE Ratio without NRI was 162.71. The lowest was 13.82. And the median was 39.12.


Daiichinkyo Co Price-to-Owner-Earnings Historical Data

The historical data trend for Daiichinkyo Co's Price-to-Owner-Earnings can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Daiichinkyo Co Price-to-Owner-Earnings Chart

Daiichinkyo Co Annual Data
Trend Mar15 Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24
Price-to-Owner-Earnings
Get a 7-Day Free Trial Premium Member Only Premium Member Only 24.75 35.43 70.26 260.93 -

Daiichinkyo Co Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Price-to-Owner-Earnings Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 260.93 144.77 94.24 16.78 -

Competitive Comparison of Daiichinkyo Co's Price-to-Owner-Earnings

For the Drug Manufacturers - General subindustry, Daiichinkyo Co's Price-to-Owner-Earnings, along with its competitors' market caps and Price-to-Owner-Earnings data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Daiichinkyo Co's Price-to-Owner-Earnings Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Daiichinkyo Co's Price-to-Owner-Earnings distribution charts can be found below:

* The bar in red indicates where Daiichinkyo Co's Price-to-Owner-Earnings falls into.



Daiichinkyo Co Price-to-Owner-Earnings Calculation

In 1986 Berkshire Hathaway Shareholder Letter, Warren Buffett defined owner earnings as follows:

"These represent (a) reported earnings plus (b) depreciation, depletion, amortization, and certain other non-cash charges...less (c) the average annual amount of capitalized expenditures for plant and equipment, etc. that the business requires to fully maintain its long-term competitive position and its unit volume. (If the business requires additional working capital to maintain its competitive position and unit volume, the increment also should be included in (c))...Our owner-earnings equation does not yield the deceptively precise figures provided by GAAP, since (c) must be a guess - and one sometimes very difficult to make. Despite this problem, we consider the owner earnings figure, not the GAAP figure, to be the relevant item for valuation purposes - both for investors in buying stocks and for managers in buying entire businesses...All of this points up the absurdity of the 'cash flow' numbers that are often set forth in Wall Street reports. These numbers routinely include (a) plus (b) - but do not subtract (c)."

Daiichinkyo Co's Price-to-Owner-Earnings for today is calculated as

Price-to-Owner-Earnings=Share Price/Owner Earnings per Share (TTM)
=30.86/1.50
=20.57

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Daiichinkyo Co  (OTCPK:DSNKY) Price-to-Owner-Earnings Explanation

For how to get Owner Earnings per Share (TTM), please click.


Daiichinkyo Co Price-to-Owner-Earnings Related Terms

Thank you for viewing the detailed overview of Daiichinkyo Co's Price-to-Owner-Earnings provided by GuruFocus.com. Please click on the following links to see related term pages.


Daiichinkyo Co (Daiichinkyo Co) Business Description

Traded in Other Exchanges
Address
3-5-1, Nihonbashi-honcho, Chuo-ku, Tokyo, JPN, 103-8426
Daiichi Sankyo was established by the merger of Daiichi Pharmaceuticals and Sankyo in 2005. As of 2021, approximately half of revenue comes from its Japan businesses, which will shrink in the future as the company expands its global footprint. Its primary growth driver is its leading platform of antibody drug conjugates. Its three lead ADCs are Enhertu (HER2), Dato-DXd (TROP2), I-DXd (B7-H3), HER3-DXd (HER3), and R-DXd (CDH6). Enhertu entered the clinic in 2015 and received its first U.S approval in December 2019 for third-line late-stage HER2-positive breast cancer. It is also approved for HER2-positive stomach cancers and HER2 mutant non-small cell lung cancer.